Philippe Seguela

Title: Philippe Seguela: Innovator in Ion Channel Receptors

Introduction

Philippe Seguela is a notable inventor based in Outremont, Canada. He has made significant contributions to the field of ion channel receptors, particularly through his innovative patent related to heteromultimeric ion channels.

Latest Patents

Philippe Seguela holds a patent for a "Heteromultimeric ion channel receptor and uses thereof." This invention describes a heteromultimeric proton-gated ion channel, referred to as ASIC-2S.2, which possesses distinctive properties. The patent outlines compositions and methods for producing and expressing functional ASIC-2S.2 channels, which are composed of ASIC2A and ASIC3 subunits. Additionally, it provides genetically engineered expression vectors that include nucleic acid sequences encoding both ASIC2A and ASIC3, as well as host cells that coexpress these subunits. The invention also discusses the use of ASIC-2S.2, along with agonists, antagonists, or antibodies that specifically bind to ASIC-2S.2, in the diagnosis, prevention, and treatment of diseases associated with its expression. Furthermore, methods for influencing the electrophysiological, pharmacological, and functional properties of ASIC-2S.2 are disclosed, along with techniques for screening substances that can modulate ion-channel activity.

Career Highlights

Philippe Seguela is affiliated with McGill University, where he continues to advance research in the field of ion channels. His work has garnered attention for its potential applications in medical science and pharmacology.

Collaborations

Philippe Seguela has collaborated with Kazimierz Babinski, contributing to the development and understanding of ion channel receptors.

Conclusion

Philippe Seguela's innovative work in the field of ion channel receptors exemplifies the impact of scientific research on medical advancements. His patent for ASIC-2S.2 highlights the potential for new therapeutic approaches in treating diseases related to ion channel dysfunction.